Eli Lilly and Company

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Eli Lilly and Company (LLY) on Behalf of Investors

Retrieved on: 
Tuesday, October 20, 2020
Legal, Professional services, Given names, INDIANA, Health, Eli Lilly and Company, LLY, Remdesivir, Lilly, Eli

Law Offices of Howard G. Smith continues its investigation on behalf of Eli Lilly and Company (Eli Lilly or the Company) (NYSE: LLY ) investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith continues its investigation on behalf of Eli Lilly and Company (Eli Lilly or the Company) (NYSE: LLY ) investors concerning the Companys possible violations of federal securities laws.
  • In August 2020, the Company began a clinical trial to test whether adding the Company's antibody-based drug, LY-CoV555, to remdesivir would benefit patients diagnosed with COVID-19.
  • On this news, Eli Lillys stock price fell $4.41, or 2.8%, to close at $150.08 per share on October 13, 2020.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Eli Lilly and Company (LLY) on Behalf of Investors

Retrieved on: 
Monday, October 19, 2020
Legal, Professional services, INDIANA, Eli Lilly and Company, LLY, Eli Lilly, States of the United States, Midwestern United States

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, continues its investigation on behalf of Eli Lilly and Company (Eli Lilly or the Company) (NYSE: LLY ) investors concerning the Companys possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, continues its investigation on behalf of Eli Lilly and Company (Eli Lilly or the Company) (NYSE: LLY ) investors concerning the Companys possible violations of the federal securities laws.
  • In August 2020, Eli Lilly began a clinical trial to test whether adding the Company's antibody-based drug, LY-CoV555, to remdesivir would benefit patients diagnosed with COVID-19.
  • On this news, the Company's stock price fell $4.41, or 2.8%, to close at $150.08 per share on October 13, 2020.
  • Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation.

Dr. Sid Kerkar Joins EXUMA Biotech as Vice President Oncology, R&D, Company Presents Data on HER2-Targeting CAR-T at AACR Tumor Immunology and Immunotherapy Conference

Retrieved on: 
Monday, October 19, 2020
Health, Articles, Bristol Myers Squibb, Eli Lilly and Company, Pharmaceutical industry in India, Pharmaceutical industry in China

Dr. Kerkar will report to EXUMA Biotech Chairman and CEO Dr. Gregory Frost, Ph.D., and will be based in West Palm Beach, Florida.

Key Points: 
  • Dr. Kerkar will report to EXUMA Biotech Chairman and CEO Dr. Gregory Frost, Ph.D., and will be based in West Palm Beach, Florida.
  • Dr. Kerkar joins EXUMA from Eli Lilly and Company, where he served as Associate Vice President Immuno-oncology.
  • Previously, Dr. Kerkar was at Boehringer- Ingelheim Pharmaceuticals from 2017-2019, and from 2016-2017 he was at Bristol Myers Squibb.
  • While at the Surgery Branch, Dr. Kerkar provided clinical care to patients on Dr. Steven A. Rosenberg's cancer immunotherapy protocols.

ELI LILLY AND COMPANY ALERT: Bragar Eagel & Squire, P.C. is Investigating Eli Lilly and Company on Behalf of Eli Lilly Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, October 16, 2020
Given names, Eli Lilly and Company, LLY, Lilly, Eli, INDIANA

NEW YORK, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Eli Lilly and Company (NYSE: LLY) on behalf of Eli Lilly stockholders.

Key Points: 
  • NEW YORK, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Eli Lilly and Company (NYSE: LLY) on behalf of Eli Lilly stockholders.
  • Our investigation concerns whether Eli Lilly has violated the federal securities laws and/or engaged in other unlawful business practices.
  • On August 2020, Eli Lilly began a clinical trial to test whether adding the Companys antibody-based drug, LY-CoV555, to remdesivir would benefit patients diagnosed with COVID-19.
  • On this news, the Company's stock price fell $4.41, or 2.8%, to close at $150.08 per share on October 13, 2020.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Eli Lilly and Company and Encourages Investors with Losses of $100,000 to Contact the Firm

Retrieved on: 
Thursday, October 15, 2020
Legal, Professional services, LLY, Securities Class Action, Eli Lilly and Company, Securities regulation in the United States, Financial markets, Economy of the United States, Articles

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eli Lilly and Company (Eli Lilly or the Company) (NYSE: LLY ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eli Lilly and Company (Eli Lilly or the Company) (NYSE: LLY ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • The same day, Reuters reported that FDA inspectors "uncovered serious quality control problems" at the Companys plant that will manufacture COVID-19 drugs.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Eli Lilly and Company and Encourages Investors with Losses of $100,000 to Contact the Firm

Retrieved on: 
Wednesday, October 14, 2020
Legal, Professional services, LLY, Securities Class Action, Eli Lilly and Company, Securities regulation in the United States, Financial markets, Economy of the United States, Articles

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eli Lilly and Company (Eli Lilly or the Company) (NYSE: LLY ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eli Lilly and Company (Eli Lilly or the Company) (NYSE: LLY ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • The same day, Reuters reported that FDA inspectors "uncovered serious quality control problems" at the Companys plant that will manufacture COVID-19 drugs.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

The Law Offices of Frank R. Cruz Announces Investigation of Eli Lilly and Company (LLY) on Behalf of Investors

Retrieved on: 
Wednesday, October 14, 2020
Legal, Professional services, Given names, INDIANA, Health, LLY, Eli Lilly and Company, Lilly, Eli, Remdesivir

The Law Offices of Frank R. Cruz announces an investigation of Eli Lilly and Company (Eli Lilly or the Company) (NYSE: LLY ) on behalf of investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • The Law Offices of Frank R. Cruz announces an investigation of Eli Lilly and Company (Eli Lilly or the Company) (NYSE: LLY ) on behalf of investors concerning the Companys possible violations of federal securities laws.
  • In August 2020, the Company began a clinical trial to test whether adding the Company's antibody-based drug, LY-CoV555, to remdesivir would benefit patients diagnosed with COVID-19.
  • On this news, Eli Lillys stock price fell $4.41, or 2.8%, to close at $150.08 per share on October 13, 2020.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Eli Lilly and Company (LLY) on Behalf of Investors

Retrieved on: 
Wednesday, October 14, 2020
Legal, Professional services, Given names, INDIANA, Health, Eli Lilly and Company, LLY, Lilly, Remdesivir, Eli

Law Offices of Howard G. Smith announces an investigation on behalf of Eli Lilly and Company (Eli Lilly or the Company) (NYSE: LLY ) investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith announces an investigation on behalf of Eli Lilly and Company (Eli Lilly or the Company) (NYSE: LLY ) investors concerning the Companys possible violations of federal securities laws.
  • In August 2020, the Company began a clinical trial to test whether adding the Company's antibody-based drug, LY-CoV555, to remdesivir would benefit patients diagnosed with COVID-19.
  • On this news, Eli Lillys stock price fell $4.41, or 2.8%, to close at $150.08 per share on October 13, 2020.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Eli Lilly and Company (LLY) on Behalf of Investors

Retrieved on: 
Wednesday, October 14, 2020
Legal, Professional services, INDIANA, Eli Lilly and Company, LLY, Eli Lilly, States of the United States, Midwestern United States

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Eli Lilly and Company (Eli Lilly or the Company) (NYSE: LLY ) investors concerning the Companys possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Eli Lilly and Company (Eli Lilly or the Company) (NYSE: LLY ) investors concerning the Companys possible violations of the federal securities laws.
  • In August 2020, Eli Lilly began a clinical trial to test whether adding the Company's antibody-based drug, LY-CoV555, to remdesivir would benefit patients diagnosed with COVID-19.
  • On this news, the Company's stock price fell $4.41, or 2.8%, to close at $150.08 per share on October 13, 2020.
  • Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation.

Lilly Confirms Date and Conference Call for Third-Quarter 2020 Financial Results Announcement

Retrieved on: 
Thursday, October 8, 2020
INDIANA, States of the United States, Midwestern United States, Eli Lilly and Company, LLY, Eli Lilly, Lilly, New York Stock Exchange, Indianapolis

INDIANAPOLIS, Oct.8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2020 financial results on Tuesday, October 27, 2020.

Key Points: 
  • INDIANAPOLIS, Oct.8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2020 financial results on Tuesday, October 27, 2020.
  • Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.
  • The conference call will begin at 9 a.m. Eastern time.
  • Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world.